Which antihistamines are government subsidized in New Zealand?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Government Subsidized Antihistamines in New Zealand

Based on the available evidence, I cannot determine which antihistamines are government subsidized in New Zealand as this specific information is not provided in the evidence.

The evidence provided does not contain information about New Zealand's pharmaceutical subsidy system or which antihistamines are covered under government funding in New Zealand. The evidence primarily discusses clinical aspects of antihistamines including:

Types of Antihistamines Mentioned

First-Generation (Sedating) Antihistamines:

  • Diphenhydramine (Benadryl)
  • Chlorphenamine (chlorpheniramine)
  • Hydroxyzine
  • Brompheniramine
  • Clemastine
  • Cyproheptadine
  • Promethazine
  • Triprolidine
  • Doxepin

Second-Generation (Non-sedating) Antihistamines:

  • Cetirizine
  • Loratadine
  • Fexofenadine
  • Desloratadine
  • Levocetirizine
  • Acrivastine
  • Azelastine (intranasal)
  • Olopatadine (intranasal)

Clinical Considerations

The evidence discusses important clinical aspects of antihistamine selection:

  1. Second-generation antihistamines are generally preferred due to their reduced sedative effects 1

  2. Among second-generation antihistamines:

    • Fexofenadine, loratadine, and desloratadine do not cause sedation at recommended doses
    • Cetirizine may cause mild sedation (13.7% vs 6.3% placebo) 1
  3. First-generation antihistamines have significant drawbacks:

    • Cause sedation and performance impairment
    • Have anticholinergic effects
    • Should be avoided in elderly patients 1
  4. Special populations:

    • In renal impairment: Acrivastine should be avoided; cetirizine and levocetirizine doses should be halved 1
    • In hepatic impairment: Mizolastine is contraindicated; chlorphenamine and hydroxyzine should be avoided in severe disease 1
    • In pregnancy: All antihistamines should ideally be avoided, especially in first trimester 1

To determine which antihistamines are government subsidized in New Zealand, you would need to consult the New Zealand Pharmaceutical Management Agency (PHARMAC) formulary or the New Zealand Pharmaceutical Schedule, which are not provided in the evidence.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.